Clinical Trial Detail

NCT ID NCT03455764
Title A Phase I/II Study of MCS110 With BRAF/MEK Inhibition in Patients With Melanoma After Progression on BRAF/MEK Inhibition
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

melanoma

Therapies

Dabrafenib + MCS110 + Trametinib

Age Groups: senior adult

Additional content available in CKB BOOST